Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics for immune‑mediated inflammatory diseases, has emerged from stealth with an oversubscribed Series A financing of $165 million co‑led by Jeito Capital and Sofinnova Partners.
The company is helmed by Frédéric Marrache, MD, PhD, MBA, a former Sanofi executive who was head of immunology R&D at Sanofi, and focuses initially on atopic dermatitis and inflammatory bowel disease (IBD).
Bionyra’s launch is built around three licensed immunology and inflammation (I&I) assets—all monoclonal or multispecific antibodies—licensed from Chinese and U.S. firms, including two next‑generation monoclonal and bispecific antibodies from TrueLab Biopharmaceutical valued up to $985 million in potential milestones.
The $165‑million round will fund clinical advancement of these assets, with plans to move all three into Phase 1 trials by the end of 2026, generate proof‑of‑concept data by 2028, and expand additional preclinical programs in severe immune‑mediated inflammatory diseases.
Sources:
Bionyra emerges with $165M and three licensed I&I assets
Bionyra brings in $165M for next-generation immune drugs
Sanofi swaps R&D leaders; Merck's Prometheus deal pays dividends
TrueLab Biopharmaceutical anuncia un acuerdo de licencia con Bionyra Pharma (1)
Top I&I deals so far in 2024 - PharmaLive
Bionyra Pharma - Fierce Biotech
I&I Investment Ramps Up With Novel Targets and Boundless ...